Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

HPV vaccine shows evidence of herd protection

The HPV vaccine not only has resulted in a decrease in human papillomavirus infection in immunized teens but also in teens who were not immunized.

9 Jul 2012

Cancer Therapeutics reveals proof of concept for second development drug

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.

4 Jul 2012

CAP/ASCCP LAST Project recommendations for better diagnosis of HPV-associated lesions

The College of American Pathologists (CAP) and the American Society for Colposcopy and Cervical Pathology (ASCCP) jointly issued The Lower Anogenital Squamous Terminology (LAST) Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations.

4 Jul 2012

Study investigates association between SCC and cutaneous HPV types belonging to five different genera

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida, the German Cancer Research Center in Heidelberg, and the International Agency for Research on Cancer in Lyon, France, conducted a case control study and found associations between having antibodies to certain types of cutaneous human papillomavirus (HPV) and a kind of skin cancer called squamous cell carcinoma (SCC).

2 Jul 2012

Association between SCC and cutaneous HPV types

29 Jun 2012

Oral health may be linked to HPV status of head and neck cancer

The chronic oral inflammatory disease periodontitis may be associated with human papillomavirus status in individuals with head and neck squamous cell carcinoma, report researchers.

28 Jun 2012

Nanoparticles that can slip through mucus barriers shown to protect against herpes infections

Johns Hopkins researchers say they have demonstrated, for the first time in animals, that nanoparticles can slip through mucus to deliver drugs directly to tissue surfaces in need of protection. The researchers used these mucus-penetrating particles (MPPs) to protect against vaginal herpes infections in mice and the goal is to create similar MPPs to deliver drugs that protect humans against sexually transmitted diseases or even treat cancer.

26 Jun 2012

Having antibodies for cutaneous HPV and sun exposure can act synergistically in BCC, SCC

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and the German Cancer Research Center in Heidelberg have found that having antibodies for cutaneous types of human papillomavirus (HPV), coupled with sun exposure (ultraviolet radiation) or poor tanning ability, can act "synergistically" in the development of non-melanoma skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

26 Jun 2012

Cellular source of cervical cancer found

A team of scientists from A*STAR's Institute of Medical Biology (IMB) and Genome Institute of Singapore (GIS) together with clinicians from Boston's Brigham and Women's Hospital (BWH) have identified a unique set of cells in the cervix that are the cause of human papillomaviruses (HPV) related cervical cancers. Significantly, the team also showed that these cells do not regenerate when excised.

12 Jun 2012

New synthetic vaccine effective in killing HPV-derived cancer

Researchers at Moffitt Cancer Center have developed and tested in mice a synthetic vaccine and found it effective in killing human papillomavirus-derived cancer, a virus linked to cervical cancers among others.

10 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

Study reveals variability in physician intentions and recommendations on HPV vaccination

Researchers at Moffitt Cancer Center surveyed 1,008 physicians seeking their knowledge, recommendation beliefs and information on their practices regarding the controversial human papillomavirus (HPV) vaccine, which is aimed at preventing cancers resulting from sexually transmitted HPV infection. Of the physicians surveyed, 112 provided additional comments at the conclusion of the survey.

14 May 2012

Treatable infections responsible for nearly 2M cases of cancer globally each year, study suggests

"Bacteria, viruses and parasites cause around two million cases of cancer in the world each year, experts believe," the Press Association/Guardian reports. According to the news service, "Scientists carried out a statistical analysis of cancer incidence to calculate that around 16 percent of all cancers diagnosed in 2008 were infection-related," and "the proportion of cancers linked to infection was three times higher in developing countries than in developed ones."

10 May 2012

Inovio first quarter total revenue decreases to $1.7 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.

10 May 2012

One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

9 May 2012

School-based health centers highly effective in delivering comprehensive care

New research from the University of Colorado School of Medicine shows that school-based health centers are highly effective in delivering comprehensive care, especially vaccines to adolescents.

7 May 2012

Study reveals steepest decline in HPV vaccine completion among girls

The proportion of insured girls and young women completing the human papillomavirus (HPV) vaccine among those who initiated the series has dropped significantly - as much as 63 percent - since the vaccine was approved in 2006, according to new research from the University of Texas Medical Branch (UTMB) in Galveston.

5 May 2012

Inovio's SynCon vaccine for cervical dysplasias and cancers granted U.S. patent

Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering Inovio's SynCon vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV).

2 May 2012

Hologic enters definitive agreement to acquire Gen-Probe

Hologic, Inc. and Gen-Probe Incorporated today announced that their Boards of Directors have unanimously approved a definitive agreement under which Hologic will acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion.

From Hologic, Inc. 30 Apr 2012